论文部分内容阅读
目的探讨厄贝沙坦联合螺内酯治疗围生期心肌病的治疗效果。方法40例经常规洋地黄、利尿剂、血管扩张药等治疗效果欠佳的围生期心肌病患者,给予口服厄贝沙坦75～225mg/d,螺内酯40mg/d,治疗4周后观察治疗前后心率、血压、心胸比、左室射血分数、左室舒张未期内径以及心功能的变化。结果治疗后心率、血压、心胸比以及左室舒张未期内径均明显下降(P<0.05),左室射血分数增加(P<0.01),心功能改善1～2级,药物不良反应少,患者耐受性好。结论厄贝沙坦联合螺内酯治疗围生期心肌病疗效好,不良反应少,值得临床推广。
Objective To investigate the therapeutic effect of irbesartan and spironolactone on perinatal cardiomyopathy. Methods Forty patients with perinatal cardiomyopathy underwent routine treatment with digitalis, diuretics and vasodilators were given oral irbesartan 75 ~ 225mg / d and spironolactone 40mg / d for 4 weeks after treatment Heart rate before and after, blood pressure, cardiothoracic ratio, left ventricular ejection fraction, left ventricular diastolic diameter and cardiac function changes. Results After treatment, the heart rate, blood pressure, cardiothoracic ratio and left ventricular diastolic diameter were significantly decreased (P <0.05), left ventricular ejection fraction increased (P <0.01), heart function improved 1 ~ 2, adverse drug reactions, Patients are well tolerated. Conclusion Irbesartan combined with spironolactone in the treatment of perinatal cardiomyopathy has good curative effect and few adverse reactions, which deserves clinical promotion.